Skip to main content
S&P 5007,697.46+0.35%DOW51,406.46+0.11%NASDAQ26,949.23+0.57%BTC$84,653.00+0.63%ETH$2,702.77-0.92%GOLD$4,224.70+1.08%OIL$91.44+2.30%
Smart Investors Daily
RC

NYSE · RCUS

Arcus Biosciences, Inc.

Healthcare · Biotechnology

$25.65

Up+$0.64 (+2.56%)

Updated Sep 30, 2026, 1:27 PM

SID Score

5.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.72B
P/E ratio
-7.68
Dividend yield
0.00%
52-week range
$12.87 – $31.74
Volume
1.25M
Avg. volume
1.53M

Price performance · RCUS

RCUS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 29, 2026

RCUS closed at $25.65 after 20 trading sessions, down 13.67% for the selected period.

Last close
$25.65
Period change
-13.67%
Period low
$24.07
Period high
$30.13
Daily close
View OHLC price history
RCUS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 29, 2026$24.93$26.04$24.76$25.651.25M
Sep 28, 2026$24.85$25.505$24.35$25.011.25M
Sep 25, 2026$25.16$25.29$24.335$24.971.72M
Sep 24, 2026$26.20$26.49$24.42$25.062.04M
Sep 23, 2026$26.86$27.90$25.845$26.391.56M
Sep 22, 2026$26.34$27.11$26.04$26.871.39M
Sep 21, 2026$25.54$26.03$25.06$25.951.11M
Sep 18, 2026$25.74$25.74$25.02$25.242.9M
Sep 17, 2026$25.31$25.92$25.05$25.542.01M
Sep 16, 2026$24.79$25.28$24.18$24.652.3M
Sep 15, 2026$23.89$24.35$23.31$24.321.93M
Sep 14, 2026$24.59$24.99$24.02$24.071.72M
Sep 11, 2026$26.50$26.58$24.315$24.594.28M
Sep 10, 2026$28.02$28.455$25.91$26.152.39M
Sep 9, 2026$28.71$29.30$28.20$28.491.83M
Sep 8, 2026$29.21$29.50$28.79$29.061.36M
Sep 4, 2026$29.64$30.10$29.40$29.66736.98K
Sep 3, 2026$29.92$30.20$29.195$30.13681.7K
Sep 2, 2026$30.17$31.47$29.32$29.851.23M
Sep 1, 2026$29.18$29.87$28.68$29.711.53M

Latest RCUS news

The latest Smart Investors Daily articles mentioning RCUS.

Stock researchCompany · Overview

Company

OverviewForecastEarnings — requires Earnings Calls and Results accessDividend — requires Dividend Research accessFinancials

Market Activity

OptionsInsider Trades — requires Insider Buying and Selling accessShort InterestInstitutional Ownership — requires Institutional Ownership accessSentiment

RCUS research

Overview

Company profile and research snapshot.

Company profile

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.50
Implied upside
—
Analysts
—
RCUS recent ratings
DateFirmRatingTarget
Sep 16, 2026TD CowenBuy—
Sep 8, 2026Truist SecuritiesBuy—
Aug 6, 2026WedbushOutperform—
Aug 6, 2026Wells FargoEqual-Weight—
Jul 20, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

HAYWARD, Calif., September 22, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City.

Yahoo · Sep 9, 2026

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., September 09, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company’s common stock at an exercise price per share of $29.06, which was t

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By